GreenLight Biosciences's operating income is $-160M.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2023
Trailing 12 months ending Mar 31, 2023
GreenLight Biosciences posts a operating income of $-160M as of March 2023. That compares with $-29M in the prior-year period — down 438.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, GreenLight Biosciences's operating income was $-29M. The latest reading is $-160M — a 438.0% year-over-year decrease (period ending March 2023). Use the history and growth charts on this page for a longer lookback.
Operating Income is one piece of GreenLight Biosciences's financial statement story. At $-160M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for GRNA's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; GreenLight Biosciences's other metric pages and overview cover the third.